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Introduction: Recent developments of diffusion-weighted magnetic
resonance imaging (DWI) make it possible to image malignant
tumors to provide tissue contrast based on difference in the diffusion
of water molecules among tissues, which can be measured by
apparent diffusion coefficient (ADC) value. The aim of this study is
to examine the usefulness of DWI for benign/malignant discrimina-
tion of pulmonary nodules/masses compared with 18F-fluorodeoxy-
glucose (FDG) positron emission tomography (PET).
Methods: PET and DWI were carried out prospectively in 104
patients with 140 pulmonary nodules/masses before surgery. FDG
uptake of each lesion was quantitatively measured by a contrast ratio
of standard uptake value (SUV-CR) between the lesions and con-
tralateral lung. Diffusion of water molecule in each lesion was
quantitatively measured by a minimum ADC (ADC-min). The diag-
nostic results were compared between the two modalities.
Results: The receiver operating characteristics curve showed cutoff
values of the ADC-min and the SUV-CR for benign/malignant
discrimination to be 1.1  103 mm2/s and 0.37, respectively. DWI
and PET showed sensitivities of 0.70 and 0.72 and specificities of
0.97 and 0.79, respectively. Although there was no significant
difference in sensitivity between the two methods, DWI showed a
significantly higher specificity than PET because of fewer false-
positives for active inflammatory lesions (p  0.03). The ADC-min
and SUV-CR values showed a significant reverse correlation (r 
0.504, p  0.001).
Conclusions: DWI may be able to be used in place of FDG-PET to
distinguish malignant from benign pulmonary nodules/masses with
fewer false-positive results compared with FDG-PET.
Key Words: Diffusion-weighted imaging, Magnetic resonance im-
aging, Fluorodeoxyglucose, Positron emission tomography, Pulmo-
nary nodules, Lung cancer.
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In recent years, positron emission tomography (PET) using18F-fluorodeoxyglucose (FDG) has made a useful contribu-
tion to the discrimination of malignant from benign pulmo-
nary nodules.1–3 However, PET has given false-negative
results for well-differentiated pulmonary adenocarcinoma4,5
and false-positive for inflammatory nodules.6,7
Recent advances in magnetic resonance (MR) gradient
technology allow acquisition of diffusion-weighted MR im-
aging (DWI), which provides excellent tissue contrast based
on difference in the diffusion of water molecules among
tissues8–10 and is different from ordinary T1- and T2-weighted
images. Because the diffusion of water molecules is disturbed by
intracellular organelles and macromolecules, any architectural
changes in the proportion of extracellular to intracellular water
molecules will alter the signal intensity of DWI and the apparent
diffusion coefficient (ADC) of the tissues.11–13 Malignant tumors
have increased cellularity, larger nuclei with more abundant
macromolecular proteins, larger nuclear cytoplasmic (N/C) ratio,
and less extracellular space, compared with normal tissue.
Therefore, diffusion of water molecules in malignant tumors is
restricted compared with that in normal tissue, resulting in a
decreased ADC value.14–17
Although the clinical utility of DWI was initially es-
tablished in the central nervous system, its application to the
body organs has been considered difficult, because DWI is
highly sensitive to motion artifacts caused by breathing and
movement of the heart and aorta.18 However, the recent
development of fast imaging techniques such as echoplanar
imaging and parallel imaging technique has improved DWI in
body organs.17,19,20 In addition, three-dimensional (3D) dis-
play of DWI with a reversed gray scale can produce images
similar to PET images.16 The further recent development of
fusion software, which displays DWI onto ordinary MR
images, enables easy identification of the location of regions
with intense signal on DWI. Clinical study of DWI has been
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reported in head and neck tumors,13,21 breast tumors,22 mus-
culoskeletal system,23–25 prostate cancer,26 rectal cancer,27
and lung cancer.28–30 However, there have been no reports
excluding one analyzed twelve cases with lung cancer by
Komori et al.,29 which examine the usefulness of DWI compar-
ing with FDG-PET. In this study, we evaluated the sensitivity
and specificity of DWI for benign/malignant discrimination of
pulmonary nodules/masses, comparing with FDG-PET.
MATERIALS AND METHODS
Eligibility
The study protocol for examining FDG-PET and DWI
in patients with suspected non-small cell lung cancer
(NSCLC) before surgery was approved by the Ethical Com-
mittee of Kumamoto University Hospital in January 2006.
Informed consent was obtained from all patients after dis-
cussing the risks and benefits of the study with their surgeons.
Patients
Between February 2006 and July 2007, 114 patients
with 165 pulmonary nodules/masses prospectively underwent
FDG-PET and DWI within a 2-week interval. Of these 165
lesions, 25 with a pure ground-glass opacity (GGO) appear-
ance were excluded because all pure GGO nodules were
negative on both DWI and PET in this study. GGO with solid
part, i.e., mixed GGO, were included in this study. As a
result, 140 nodules/masses in 104 patients were entered in the
study (Table 1). There were 55 men and 49 women with their
mean age of 68  13-year-old (median, 70; range, 20–80-
year-old). Of the 140 lesions, 118 were diagnosed histologi-
cally after surgical resection, whereas the other 22 were
diagnosed as old inflammation because their sizes had been
unchanged for more than 2 years upon review of retrospective
chest x-ray films or CT. Mean follow-up duration of these 22
nodules, of which 6 nodules were checked by x-ray and the
other 16 nodules by CT, was 41  23 months (range, 24–97
months). Mean size of these 22 nodules was 1.4  0.6 cm
(range, 1.0–3.5 cm). None of the 140 lesions had apparent
cavitations and calcifications on CT. Long-axis diameter of
pulmonary nodules/masses was selected as size of the lesions.
PET-CT Scanning
Patients were instructed to fast for at least 5 hours
before intravenous administration of FDG. The dose of FDG
administered was 100 Ci/kg (3.7 MBq/kg) of body weight.
PET imaging was performed approximately 60 minutes after
intravenous administration of the FDG using an integrated
PET/CT device (Discovery ST; GE Medical Systems) that
consisted of a PET scanner (Advance Nx; GE Medical
Systems) and an eight section CT scanner (Light Speed Plus;
GE Medical Systems). All images were acquired under shal-
low-breathing conditions.
The acquisition time for PET in 3D mode was 3 minutes
per table position. CT data were resized from a 512  512
matrix to a 128  128 matrix to match the PET data to allow
image fusion, and a CT transmission map was generated. PET
image data was reconstructed iteratively using the ordered sub-
sets expectation-maximization algorithm with segmented atten-
uation correction (4 iterations, 28 subsets) and the CT data. The
3.75-mm-thick transaxial CT images were reconstructed at 3.27
mm intervals (transaxial) for fusion with the transaxial PET
images. The PET, CT, and fused images were available for
review in the axial, coronal, and sagittal planes using Xeleris
software (GE Medical Systems) on a computer workstation.
Diffusion-Weighted Imaging
All MR images were obtained with a 1.5 T supercon-
ducting system (Gyroscan Intera Achieva Nova Dual; Philips
Medical Systems, the Netherlands). Conventional MR images
and DWI were acquired during the same procedure. The
conventional MR images consisted of a coronal T1-weighted
sequence (repetition time [TR] ms/echo time [TE] ms/exci-
tations, 234/4/1), and coronal and axial single shot spin echo
T2-weighted (800/90/1), and coronal and axial short tau
inversion recovery (TR/TE/inversion time, 4600/90/160) se-
quences. The T1-weighted, T2-weighted, and short tau inver-
sion recovery sequences were acquired at a section thickness
of 6 mm with a 1-mm intersection gap, a 128  128 to 256
matrix, and a 40 to 45 cm field of view. All images were
acquired under shallow-breathing conditions.
DWI was performed in the transverse plane using a
spin-echo, echo-planar imaging sequence with the following
parameters: TR/TE/flip angle, 5900/60/90; diffusion gradient
encoding in three orthogonal directions; b  1000 s/mm2; field
of view, 400 mm; matrix size, 112  100; section thickness, 6
mm; section gap, 1 mm; and number of signals acquired, 6.
PET Data Analysis
Two radiologists (K.K., and S.S., with 14 and 11 years
respectively of radioisotope scintigraphy and PET experi-
ences) who were unaware of the patients’ clinical data eval-
uated the PET-CT data. A consensus was reached if there was
any difference of their opinions. After image reconstruction,
two-dimensional (2D) circular region of interest (ROI) was
drawn in a slice where the highest count was detected visually
TABLE 1. Characteristics of Pulmonary Nodules/Masses
Malignant (n  106)
Primary lung cancer
Adenocarcinoma 66
Squamous-cell carcinoma 21
Adenosquamous carcinoma 3
Lymphoepithelioma-like carcinoma 1
Carcinoid 1
Metastatic lung tumor 14
Benign (n  34)
Benign lung tumor
Hamartoma 1
Schwannoma 1
Inflammation
Active 6
Chronic 24
Intrapulmonary lymph node 1
Amyloid nodule 1
Total 140
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with fused CT image. From these ROI, the maximum SUV
value (SUVmax) was calculated. Then, the contrast ratio of SUV
(SUV-CR), was calculated as described previously.7,31 Briefly,
the ROI were placed on the lesions and at the equivalent point
in the contralateral lung. The highest pixel value in the tumor
ROI (T) and in the contralateral normal lung ROI (N) were
measured. The SUV-CR was calculated by (T  N)/(T  N) in
each lesion as an index of FDG-uptake.
DWI Data Analysis
One radiologist (K.K., 17 years of MRI experience)
who was unaware of the patients’ clinical data evaluated the
MR image. DWI data were evaluated semiquantitatively
using ADC. The ADC was calculated as follows: ADC 
[In(S/S0)]/b, where S is the signal intensity of the ROI
obtained through three orthogonally oriented DWIs or diffu-
sion trace images, and b is a gradient b factor with a value of
1000 s/m2. After image reconstruction, 2D square ROI was
drawn in a slice where the lesion was detected visually with
reference to the T2-weghted image or CT. From the ROI, the
minimum ADC value (ADC-min) was calculated. The mean
ADC was not used, because the value within entire tumor might
not characterize the tumor because of its heterogeneity.10
Determining the Cutoff Value of ADC-Min
and SUV-CR
A receiver operating characteristics curve was con-
structed according to the SUV-CR and ADC-min using SPSS
software (SPSS 15.0 J for Windows, SPSS, Chicago, IL), and
the cutoff values were determined for benign/malignant dis-
crimination. Lesions with more than the cutoff value of
SUV-CR were defined as positive on PET-CT. Lesions with
less than the cutoff value of ADC-min were defined as
positive on DWI.
Statistical Analysis
The unpaired t test and Fisher exact test were used to
compare the distribution of size between malignant and
benign lesions. True-positive (TP), true-negative (TN), false-
positive (FP), and false-negative (FN) results of PET-CT and
DWI images for detecting pulmonary malignancies were
compared with the pathologic diagnosis. Sensitivity was
calculated as TP/TP  FN, specificity as TN/TN  FP, and
accuracy as TP  TN/total, and differences between DWI
and PET were analyzed using the McNemar test. The rela-
tionship between ADC-min and SUV-CR values was ana-
lyzed using Pearson’s r test. Statistical analysis was per-
formed using the SPSS software. All values in the text and
tables are given as mean  SD.
RESULTS
The mean size of the malignant lesion was 2.4  1.4
cm, which was significantly higher than 1.6  1.0 cm (p 
0.003) (Table 2). The number of lesions more than 3 cm in
size was 23 of the 106 (22%) malignant lesions and 2 of the
34 (6%) benign ones, of which difference was significant
(p  0.04).
DWI identified the malignant lesions clearly which was
similar to PET (Figure 1). The receiver operating character-
istics curve for the benign/malignant discrimination showed
optimal cutoff values of ADC on DWI to be 1.1  103
mm2/s and SUV-CR on PET to be 0.37 on PET (Figures
2 and 3).
In the 106 malignant lesions, DWI was positive in 74
and negative in 32, whereas PET was positive in 76 and
FIGURE 1. CT image (A), positron
emission tomography image (B),
and diffusion-weighted image (C) of
lung cancer patient.
TABLE 2. Size of the Malignant and Benign Lesions
Lesions
Size (cm)
Mean Median Range
Malignant (n  106) 2.4  1.4* 2.1 0.5–7.0
Benign (n  34) 1.6  1.0* 1.3 0.5–5.6
*p  0.003.
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negative in 30 (Table 3). Of the 53 well-differentiated ade-
nocarcinomas, 21 (40%) and 24 (45%) were negative with
DWI and PET, respectively. Of these, 15 were negative on
both DWI and PET. Of 5 malignant nodules less than 1 cm
in diameter, 2 were positive on both DWI and PET. One
was metastatic malignant melanoma of 0.9 cm in diameter
and the other was metastatic synovial sarcoma of 0.7 cm in
diameter.
Among 34 benign lesions, DWI was positive in one and
negative in 33, whereas PET was positive in 7 and negative
in 27 (Table 4). For six active inflammatory lesions, which
included one tuberculosis and five nonspecific inflammations,
DWI was positive in one (17%), whereas PET was positive in
five (83%). One lesion with active tuberculosis was positive
with both DWI and PET. All of the 24 lesions with chronic
inflammation were negative with both DWI and PET.
Tables 5 to 7 showed the data of the analyses by
McNemar test. Table 5 shows the correlation between DWI
and PET in diagnosis of malignant lesions. The sensitivities
FIGURE 2. The receiver operating characteristics curve of
ADC-min value for diagnosing malignancy for pulmonary
nodules/masses showing the optimal cutoff value to be
1.1  103 mm2/s. Area under curve: 0.907 (95% confi-
dence interval: 0.846–0.968).
FIGURE 3. The receiver operating characteristics curve of
SUV-CR for diagnosing malignancy for pulmonary nodules/
masses showing the optimal cutoff value to be 0.37. Area
under curve: 0.806 (95% confidence interval: 0.710–0.901).
TABLE 3. Findings of Diffusion-Weighted Imaging and
Positron Emission Tomography in Malignant Lesions
DWI PET
TotalPositive Negative Positive Negative
Histology
Primary lung cancer
Adenocarcinoma
Well differentiated 32 21 29 24 53
Moderately
differentiated
4 1 3 2 5
Poorly differentiated 7 1 8 0 8
Squamous cell
carcinoma
20 1 21 0 21
Adenosquamous
carcinoma
3 0 3 0 3
Lymphoepithelioma-like
carcinoma
1 0 1 0 1
Carcinoid 0 1 1 0 1
Metastatic lung tumor 7 7 10 4 14
Total 74 32 76 30 106
DWI, diffusion-weighted imaging; PET, positron emission tomography.
TABLE 4. Findings of Diffusion-Weighted Imaging and
Positron Emission Tomography in Benign Lesions
DWI PET
TotalPositive Negative Positive Negative
Histology
Benign lung tumor
Hamartoma 0 1 0 1 1
Schwannoma 0 1 1 0 1
Inflammation
Active 1 5 5 1 6
Chronic 0 24 0 24 24
Intrapulmonary
lymph node
0 1 0 1 1
Amyloid nodule 0 1 1 0 1
Total 1 33 7 27 34
DWI, diffusion-weighted imaging; PET, positron emission tomography.
TABLE 5. The Correlation Between Diffusion-Weighted
Imaging and Positron Emission Tomography for Diagnosing
Malignant Pulmonary Lesions
DWI
PET
TotalTrue-positive False-negative
True-positive 61 13 74
False-negative 15 17 32
Total 76 30 106
DWI, diffusion-weighted imaging; PET, positron emission tomography.
Sensitivity of PET  0.72 (95% confidence interval: 0.63–0.80).
Sensitivity of DWI  0.70 (95% confidence interval: 0.61–0.79).
McNemar test: p  0.85.
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of DWI and PET were 0.70 (95% CI: 0.61–0.79) and 0.72
(95% CI: 0.63–0.80), respectively, which showed no signif-
icant difference (McNemar test: p 0.85). Table 6 shows the
correlation between DWI and PET in diagnosis of benign
lesions. The specificity of DWI was 0.97 (95% CI: 0.91–
1.03), which was higher than the 0.79 (95% CI: 0.66–0.93)
with PET (McNemar test: p  0.03), due to fewer FP results.
Table 7 shows the correlation between DWI and PET in the
benign/malignant discrimination in all 140 lesions. The ac-
curacy of DWI and PET were 0.76 (95% CI: 0.69–0.84) and
0.74 (95% CI: 0.66–0.81), respectively, which showed no
significant difference (McNemar test: p  0.61).
The ADC-min and SUV-CR values showed a signifi-
cant reverse correlation with each other (r  0.504, p 
0.001) (Figure 4).
DISCUSSION
Although SUV has frequently been used for evaluation
of FDG-PET, it has been reported that several factors can
affect the SUV, such as body size,32 blood glucose level,33
and time after injection.34 We previously compared the re-
sults of SUV-max, SUV-CR with contralateral lung, and
SUV-CR with cerebellum for pulmonary nodules, and re-
ported that SUV-CR with contralateral lung or cerebellum
showed significantly higher sensitivity than SUV-max,35 a
results supported by Obrzut.36 So we selected SUV-CR with
contralateral lung for analysis in this study.
Although the sensitivity and accuracy in discriminating
malignant from benign pulmonary nodules/masses did not
differ between DWI and PET, DWI showed a higher speci-
ficity than PET because of fewer FP diagnoses for active
inflammations. Our study showed that DWI produced fewer
FPs for active inflammation than PET. While PET yielded 7
FPs (5 with active inflammation, one pulmonary schwan-
noma, and one amyloid nodule), DWI showed only one FP
for active tuberculosis. The reason for the difference may be
that nonspecific inflammation increases FDG-uptake, result-
ing in FP on PET, but does not affect the diffusion of water
molecules, resulting in TN on DWI. However, tuberculosis
gave FP on both PET and DWI, because this highly inflam-
matory condition with architectural change due to granulation
tissue increases not only the FDG-uptake on PET but also
decreases the diffusion of water molecules on DWI.
One of the deficiencies of FDG-PET in diagnosis of
lung cancer is its FN results for well-differentiated adenocar-
cinoma, which is due to their low rate of glucose-metabolism
and their low density of tumor cells.4,5,7 We previously
reported that 12 of 20 (60%) well-differentiated adenocarci-
nomas less than 3 cm in size were FN on PET.7 The present
study showed that there was no significant difference between
the two diagnostic methods for well-differentiated adenocar-
cinoma, suggesting that DWI does not improve on PET in
this regard. In addition, we excluded GGO nodules in the
present study, which are almost bronchioloalveolar carcinoma,
because air itself in GGO nodules may reduce the true ADC
value of the tumor on DWI.28 We therefore consider that
well-differentiated adenocarcinomas including bronchioloalveolar
carcinoma are difficult to be diagnosed with either PET or DWI.
There was a significant correlation between the values
of ADC-min and SUV-CR, although ADC value on DWI and
FDG-uptake on PET depend on different pathophysiologic
mechanism each other. Several authors have reported that
FDG-uptake on PET is a significant prognostic factor after
surgical treatment in patients with NSCLC.37,38 We previ-
FIGURE 4. Correlation plots between ADC-min and SUV-CR.
Open circle shows malignant and closed circle shows benign
nodule/mass. Dotted lines show cutoff value for ADC-min and
SUV-CR. The solid line shows the linear regression line and the
broken lines show 95% confidence interval. ADC-min  mini-
mum apparent diffusion coefficient; SUV-CR  contrast ratio of
standard uptake value.
TABLE 6. The Correlation Between Diffusion-Weighted
Imaging and Positron Emission Tomography for Diagnosing
Benign Pulmonary Lesions
DWI
PET
TotalTrue-negative False-positive
True-negative 27 6 33
False-positive 0 1 1
Total 27 7 34
DWI, diffusion-weighted imaging; PET, positron emission tomography.
Specificity of PET  0.79 (95% confidence interval: 0.66–0.93).
Specificity of DWI  0.97 (95% confidence interval: 0.91–1.03).
McNemar test: p  0.03.
TABLE 7. The Correlation Between Diffusion-Weighted
Imaging and Positron Emission Tomography for
Benign/Malignant Discrimination of Pulmonary Lesions
DWI
PET
TotalCorrect Incorrect
Correct 88 19 107
Incorrect 15 18 33
Total 103 37 140
DWI, diffusion-weighted imaging; PET, positron emission tomography.
Correct  true-positive  true negative.
Incorrect  false-negative  false-positive.
Accuracy of PET  0.74 (95% confidence interval: 0.66–0.81).
Accuracy of DWI  0.76 (95% confidence interval: 0.69–0.84).
McNemar test: p  0.61.
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ously reported that the SUV-CR could be used to predict the
malignant grade of lung adenocarcinoma, i.e., clinical stage
IA lung adenocarcinomas with a high SUV-CR had more
frequent lymph node metastasis, higher tumor invasiveness,
and higher proliferative activity determined by Ki-67 staining
score than those with a low SUV-CR.31,39 Because ADC
value on DWI for tumors is known to decrease with increased
cellularity, larger nuclei with more abundant macromolecular
proteins, and larger N/C ratio,14–17 we have to examine next
whether it could predict malignant grade of NSCLC similar to
FDG-uptake on PET.
This study revealed that DWI showed fewer false
positive for inflammation nodules than FDG-PET. So DWI
might be effective for probably benign lesion which showed
positive FDG-PET. But our study was based on a single 1.5
T MRI machine with small cases and nodules. Further studies
including other type of MRI machine are necessary to estab-
lish the clinical utility of DWI. MRI has the following
advantages over FDG-PET: (1) patients do not have to fast
before examination; (2) there is no radiation exposure; (3)
less time is required for the examination (30 minutes in DWI
versus 90 minutes in FDG-PET); and (4) the cost is consid-
erably less ($100 for DWI versus $700 for FDG-PET in
Japan). Although several limitations existed in our dataset,
this study showed that DWI may be able to be used in place
of PET-CT for discriminating malignant from benign pulmo-
nary nodules and is associated with significantly fewer FP
than PET-CT.
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